<DOC>
	<DOCNO>NCT00100867</DOCNO>
	<brief_summary>In clinical trial conduct throughout world , pregnant HIV-infected woman give anti-HIV drug , , give birth prevent mother-to-child transmission HIV . However , effect anti-HIV treatment infant unknown . The purpose study determine safety , toxicity , potential side effect maternal anti-HIV treatment infant bear HIV-infected woman . Study hypothesis : Specific combination antiretroviral regimen use clinical trial diverse area world safe well tolerated pregnancy breastfeed period , associate adverse side effect fetus , neonate , and/or breastfeeding infant . These regimen associate reduction mother-to-child HIV transmission .</brief_summary>
	<brief_title>Effects Maternal Anti-HIV Treatment Infants Born HIV-Infected Women</brief_title>
	<detailed_description>Many HIV-infected woman outside United States enroll clinical trial provide antiretroviral therapy ( ART ) prevent mother-to-child transmission HIV . However , data limit safety , toxicity , adverse effect maternal ART may infants bear HIV-infected woman . This study monitor adverse effect potential benefit maternal ART infant . No antiretrovirals give study . This study last 18 month . Infants enrol study within 48 hour birth . There 6 study visit start study entry every 6 week thereafter . Infants undergo blood urine collection , medical history assessment occur every visit . Mothers also evaluate visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Infant bear HIV1 infect mother enrol NIHsponsored , international antiretroviral treatment trial AND either utero postpartum antiretroviral exposure Parent guardian willing provide inform consent Infant exposure antiretrovirals OR receive intrapartum antiretroviral exposure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Perinatal Transmission</keyword>
	<keyword>Mother-to-Child Transmission</keyword>
</DOC>